These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
240 related items for PubMed ID: 8658798
1. Quadruple immunotherapy will promise excellent graft survival in cadaveric renal transplants using cardiac arrest donor grafts. Hoshinaga K, Shiroki R, Higuchi T, Horiba Y, Yanaoka M, Naide Y. Transplant Proc; 1996 Jun; 28(3):1591-3. PubMed ID: 8658798 [No Abstract] [Full Text] [Related]
2. Quadruple immunosuppressive therapy with low-dose cyclosporine provides superior kidney transplant outcome using grafts of non-heart-beating uncontrolled cadavers. Shiroki R, Hoshinaga K, Tsukiashi Y, Higuchi T, Izumitani M, Horiba M, Naide Y. Transplant Proc; 1997 Dec; 29(8):3571-3. PubMed ID: 9414841 [No Abstract] [Full Text] [Related]
3. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression. Toda F, Tanabe K, Tokumoto T, Ishikawa N, Koga S, Ito S, Yagisawa T, Toma H. Transplant Proc; 2000 Nov; 32(7):1726-9. PubMed ID: 11119909 [No Abstract] [Full Text] [Related]
4. Early fluctuation in cyclosporine A trough levels affects long-term outcome of kidney transplants. Inoue S, Beck Y, Nagao T, Uchida H. Transplant Proc; 1994 Oct; 26(5):2571-3. PubMed ID: 7940795 [No Abstract] [Full Text] [Related]
5. Long-term outcome of cadaveric kidney grafts with triple drug therapy. Amemiya H, Suzuki S, Hayashi R, Nakatani T. Transplant Proc; 1994 Aug; 26(4):2097-8. PubMed ID: 8066683 [No Abstract] [Full Text] [Related]
6. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy. Faull RJ, Bannister KM, Russ GR, Mathew TH, Clarkson AR. Transplant Proc; 1999 Aug; 31(1-2):1155-6. PubMed ID: 10083516 [No Abstract] [Full Text] [Related]
7. Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression. Tanabe K, Tokumoto T, Ishikawa N, Kanematsu A, Oshima T, Harano M, Inui M, Yagisawa T, Nakajima I, Fuchinoue S, Takahashi K, Toma H. Transplant Proc; 1999 Nov; 31(7):2877-9. PubMed ID: 10578323 [No Abstract] [Full Text] [Related]
8. Prospective randomized study of quadruple versus triple therapy in long-term kidney allografts. Fruchaud G, Buisson C, Abbou C, Desvaux D, Baron C, Benmaadi A, Chopin D, Bourgeon B, Dahmane D, Rostoker G, Weil B, Lang P. Transplant Proc; 1996 Oct; 28(5):2819. PubMed ID: 8908077 [No Abstract] [Full Text] [Related]
9. Current advantage of FK 506 in cadaveric kidney transplantation. Ciancio G, Rosen A, Loreto-Grand B, Burke G, Siquijor A, Luque C, Esquenazi V, Miller J. Transplant Proc; 1996 Apr; 28(2):1000-1. PubMed ID: 8623207 [No Abstract] [Full Text] [Related]
12. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. Kokado Y, Takahara S, Kyo M, Ichimaru N, Toki K, Wang JD, Okuyama A. Transplant Proc; 1999 Apr; 31(1-2):1151-4. PubMed ID: 10083515 [No Abstract] [Full Text] [Related]
16. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation. Kaden J, Strobelt V, May G. Transplant Proc; 1998 Dec; 30(8):4011-4. PubMed ID: 9865279 [No Abstract] [Full Text] [Related]